drugset / Trial / NCT04819412
To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus
Phase 3
Completed
1975 enrolled
Bharat Biotech International Limited
Georgia Institute for Clinical Research, LLC · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Study Rationale A single Rotavirus vaccine container with the vaccine virus and antacid buffer would be ideal for logistical, administrative and distribution ease, especially in routine immunization program. * The advantages of the liquid vaccines are: Liquid vaccines take lesser time to administer compared to the current practice of giving antacid buffer prior to vaccine which takes 40% more time to administer. * Easier to transport as it is stable at 2-80C compared to the frozen formulation that needs to be stored at -200C and transported in dry ice. * Chances of human error during administration are lesser than the sequential administration of antacid and vaccine.
Timeline
- Start
- 2015-03-20
- Primary completion
- 2015-10-30
- Completion
- 2016-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROTAVAC 5C -F1 | Vaccine | 105 unknown | — |
| Subject | ROTAVAC 5C -F2 | Vaccine | 105 unknown | — |
| Comparator | ROTAVAC® | Vaccine | 105 unknown | — |